Composition for the preventing, ameliorating or treating of edema, comprising Phellodendri Cortex extract
Phellodendron amurense extract addresses the limitations of existing lymphedema treatments by providing a composition that reduces swelling and inflammation, effectively managing lymphedema through anti-inflammatory mechanisms.
Patent Information
- Application Number
- KR1020250059216
- Authority / Receiving Office
- KR · KR
- Patent Type
- Applications
- Current Assignee / Owner
- Filing Date
- 2025-05-07
- Publication Date
- 2026-11-16
AI Technical Summary
Current treatments for lymphedema, such as NSAIDs, have failed in clinical trials and pose side effects, necessitating a safe and effective long-term management strategy.
A composition comprising Phellodendron amurense extract is developed for the prevention, improvement, or treatment of edema, including pharmaceutical, food, health functional food, cosmetic, and quasi-drug compositions, utilizing the extract's anti-inflammatory properties to reduce swelling and inflammation.
Phellodendron amurense extract significantly reduces edema size and inflammation by regulating protein expression of inflammatory cytokines and COX2, offering a safe alternative for lymphedema treatment.
Smart Images

Figure PAT00001_ABST
Abstract
Description
Technology Field
[0001] The present invention relates to a Phellodendron amurense extract, and more specifically, to the use of said Phellodendron amurense extract for the prevention, improvement, or treatment of edema. Background Technology
[0002] Lymphedema is a chronic condition characterized by the abnormal accumulation of lymphatic fluid within tissues due to the blockage of lymphatic flow caused by damage or obstruction of the lymphatic system. This edema, which primarily affects the extremities, leads to changes in the skin and subcutaneous tissue, an increased risk of infection, and functional impairment over time. While early-stage lymphedema is merely a reversible state of fluid accumulation, as the disease progresses, it is accompanied by chronic inflammation and the infiltration of immune cells, ultimately leading to tissue fibrosis.
[0003] Lymphedema exhibits complex pathological characteristics involving the simultaneous occurrence of chronic inflammation, fat accumulation, and fibrosis. Animal studies indicate that the inflammatory response, in particular, precedes lipid accumulation. If inflammation is not controlled, lipid accumulation and fibrosis worsen, further deteriorating lymphatic circulation and acting as a major factor limiting the effectiveness of treatment.
[0004] Against this backdrop, anti-inflammatory therapy is emerging as a promising strategy for the structural and functional recovery of lymphedema. Recent trends in drug research are seeking lymphedema treatments through drug repositioning. However, NSAIDs such as Ketoprofen and Bestatin have failed in clinical trials. Therefore, anti-inflammatory control using natural products composed of mixed ingredients can improve patients' quality of life and serve as a key element in long-term management strategies. The problem to be solved
[0005] Accordingly, while searching for an edema treatment that has few side effects and can be taken long-term, the inventors confirmed that Phellodendron amurense extract exhibits excellent therapeutic effects for lymphedema, thereby completing the present invention.
[0006] Therefore, the objective of the present invention is to provide a composition for the prevention, improvement, or treatment of edema comprising Phellodendron amurense extract. means of solving the problem
[0007] To achieve the above objective, the present invention provides a pharmaceutical composition for the prevention or treatment of edema comprising a Phellodendron amurense extract.
[0008] In addition, the present invention provides a food composition for the prevention or improvement of edema comprising a Phellodendron amurense extract.
[0009] In addition, the present invention provides a health functional food composition for the prevention or improvement of edema comprising a Phellodendron amurense extract.
[0010] In addition, the present invention provides a cosmetic composition for the prevention or improvement of edema comprising a Phellodendron amurense extract.
[0011] In addition, the present invention provides a quasi-drug composition for the prevention or improvement of edema comprising Phellodendron amurense extract. Effects of the invention
[0012] It was confirmed that the Phellodendron amurense extract according to the present invention significantly reduces the size of edema and exhibits anti-inflammatory effects through the regulation of protein expression of inflammatory cytokines and COX2. This implies that the Phellodendron amurense extract of the present invention effectively suppresses swelling and inflammation, and thus can be utilized in various ways in the field of treating edema and lymphedema. Brief explanation of the drawing
[0013] Figure 1 is a figure showing the results of confirming the size of lower limb lymphedema in an animal model of lymphedema administered with the Phellodendron amurense extract of the present invention. Figure 2 is a figure showing the results of confirming the protein expression of the inflammatory cytokine IL-6 in a lymphedema animal model administered with the Phellodendron amurense extract of the present invention. Figure 3 is a figure showing the results of confirming the protein expression of COX2 in a lymphedema animal model administered with the Phellodendron amurense extract of the present invention. Specific details for implementing the invention
[0014] The present invention will be described in detail below.
[0015] According to an aspect of the present invention, the present invention provides a composition for the prevention, improvement, or treatment of edema comprising a Phellodendron amurense extract.
[0016] In a specific embodiment of the present invention, the edema may be lymphedema. Lymphedema refers to a chronic disease in which lymphatic fluid abnormally accumulates within tissues as the flow of lymphatic fluid is blocked due to damage or obstruction of the lymphatic system. Lymphedema causes chronic inflammation and fibrosis in the subcutaneous tissue, leading to hardening, which in turn impairs mobility in daily life and causes recurrent skin infections. Lymphedema occurs frequently in patients who have undergone local lymph node removal or radiation therapy to prevent cancer metastasis during anticancer treatment.
[0017] In the present invention, Phellodendron amurense is also called Phellodendron amurense or Phellodendron amurense, and Phellodendron amurense RUPR. or P. chinens Schneid It is the bark of the tree peeled and dried. The above-mentioned Phellodendron bark can be used without restriction, whether cultivated or commercially available, and can be used as is after washing or after drying. As for drying methods, sun drying, shade drying, hot air drying, and natural drying can all be used.
[0018] The Phellodendron bark extract, which is the active ingredient of the composition of the present invention, can be obtained by a conventional extraction method or can be purchased and used from the market.
[0019] In the present invention, the extract is obtained by extracting from Phellodendron bark using a suitable solvent, and includes, for example, crude extracts of Phellodendron bark, extracts soluble in polar solvents, or extracts soluble in non-polar solvents. Furthermore, the concept of the extract includes all extracts, fractions, their dilutions, concentrates, or dried products obtained at each stage of extraction, fractionation, or purification.
[0020] In the present invention, a fraction refers to a result obtained by a fractionation method for separating a specific component or a specific group from a mixture containing various constituent components. In the present invention, it refers to a result obtained by a fractionation method for separating a specific component or a specific group from a Phellodendron amurense extract.
[0021] The Phellodendron amurense extract of the present invention may be obtained by extracting, isolating, and fractionating from nature using methods of extraction, isolation, and fractionation known in the art.
[0022] In a specific embodiment of the present invention, the Phellodendron bark extract is preferably extracted with one or more solvents selected from water, alcohols having 1 to 4 carbon atoms, and mixed solvents thereof. A solvent can be appropriately selected to increase the content of active ingredients contained in Phellodendron bark, allow for long-term consumption, and achieve the desired effects of preventing, improving, or treating edema. The solvent for the Phellodendron bark extract of the present invention may more preferably be ethanol, but any solvent that is pharmaceutically or food-grade acceptable may be used. Specifically, examples of the solvent include purified water, alcohols having 1 to 4 carbon atoms such as methanol, ethanol, propanol, isopropanol, and butanol, either alone or in a mixture of two or more.
[0023] The above extraction temperature is preferably 20 to 200°C. In addition, extraction methods such as room temperature extraction, hot water extraction, cold maceration extraction, reflux extraction, solvent extraction, steam distillation, ultrasonic extraction, elution, and pressing may be used, but are not limited thereto.
[0024] The above Phellodendron amurense extract can be obtained in a liquid state by cold maceration, heating, and filtration at room temperature using conventional methods known in the art, or it may be further subjected to solvent evaporation, spray drying, or freeze-drying. Additionally, the above Phellodendron amurense extract may be prepared in a powder state by additional processes such as vacuum distillation and freeze-drying or spray drying. Furthermore, the extract may be obtained as an additionally purified fraction using various chromatographic methods such as silica gel column chromatography, thin layer chromatography, and high performance liquid chromatography.
[0025] In a specific embodiment of the present invention, the composition of the present invention preferably contains Phellodendron amurense extract in an amount of 10 to 1000 mg / kg, more preferably 100 to 500 mg / kg, and even more preferably 200 mg / kg.
[0026] In a specific embodiment of the present invention, the Phellodendron amurense extract of the present invention is preferably used to reduce the size of edema, and preferably, it may reduce the size of lymphedema. In an embodiment of the present invention, the size of lymphedema was measured in an animal model of lymphedema administered the Phellodendron amurense extract of the present invention, and it was confirmed that the group administered the Phellodendron amurense extract of the present invention had significantly smaller lymphedema.
[0027] In a specific embodiment of the present invention, the Phellodendron bark extract preferably inhibits inflammation in the edematous area, and more preferably, may inhibit inflammation in the lymphedematous area. More specifically, the Phellodendron bark extract may inhibit fibrosis in the lymphedematous area by inhibiting the protein expression of IL-6 and COX2. As a result of analyzing lower limb tissue samples from a lymphedema animal model administered with the Phellodendron bark extract of the present invention, it was confirmed that the expression of inflammatory cytokines IL-6 and COX-2 was significantly reduced. This implies that the Phellodendron bark extract of the present invention inhibits inflammation, which is a major indicator of lymphedema, and thereby can prevent, improve, or treat lymphedema.
[0028] In a specific embodiment of the present invention, the composition of the present invention may be for administration to a patient who has undergone lymph node resection; or for administration to a patient who has received radiation therapy.
[0029] In summary, the inventors prepared a Phellodendron bark extract and confirmed the excellent edema-treating effect of said extract. Specifically, it was confirmed that the Phellodendron bark extract of the present invention significantly reduced swelling of the lower extremities (i.e., the size of lymphedema) in an animal model of lower extremity surgery for lymphedema, and exhibited an anti-inflammatory effect through the regulation of protein expression of inflammatory cytokines. This implies that the Phellodendron bark extract of the present invention exhibits an edema-treating effect without suppressing immunity, unlike existing drugs; thus, the Phellodendron bark extract of the present invention can be utilized in various ways in the field of edema and lymphedema treatment.
[0031] When the composition of the present invention is used as a pharmaceutical composition, the pharmaceutical composition of the present invention may be formulated into various forms according to conventional methods. For example, it may be formulated into oral formulations such as powders, granules, tablets, capsules, suspensions, emulsions, and syrups, and may be formulated into external preparations, suppositories, and sterile injectable solutions.
[0032] The composition of the present invention may contain one or more known active ingredients having a preventive or therapeutic effect on edema together with Phellodendron amurense extract.
[0033] The composition of the present invention may further include pharmaceutically acceptable additives, wherein the pharmaceutically acceptable additives may include starch, gelatinized starch, microcrystalline cellulose, lactose, povidone, colloidal silicon dioxide, calcium hydrogen phosphate, lactose, mannitol, malt syrup, gum arabic, pregelatinized starch, corn starch, powdered cellulose, hydroxypropyl cellulose, Opadry, sodium starch glycolate, carnauba wax, synthetic aluminum silicate, stearic acid, magnesium stearate, aluminum stearate, calcium stearate, sucrose, etc. The pharmaceutically acceptable additive according to the present invention is preferably included in an amount of 0.1 to 90 parts by weight with respect to the composition, but is not limited thereto.
[0034] The composition of the present invention may be administered in various oral or parenteral formulations during actual clinical administration. When formulating, it may be prepared using commonly used diluents or excipients such as fillers, extenders, binders, wetting agents, disintegrants, and surfactants. It is preferable to use a suitable formulation known in the art that is disclosed in the literature (Remington's Pharmaceutical Science, recently, Mack Publishing Company, Easton, PA).
[0035] The above-mentioned solid dosage forms for oral administration include tablets, pills, powders, granules, capsules, etc., and these solid dosage forms are prepared by mixing at least one excipient, such as starch, calcium carbonate, sucrose or lactose, gelatin, etc. In addition to simple excipients, lubricants such as magnesium styrate talc are also used. Furthermore, the above-mentioned liquid dosage forms for oral administration include suspensions, liquid formulations, emulsions, syrups, etc., and may include various excipients, such as humectants, sweeteners, flavorings, and preservatives, in addition to commonly used simple diluents such as water and liquid paraffin.
[0036] The above-mentioned formulations for parenteral administration include sterile aqueous solutions, non-aqueous solvents, suspensions, emulsions, lyophilized formulations, and suppositories. Propylene glycol, polyethylene glycol, vegetable oils such as olive oil, and injectable esters such as ethyl oleate may be used as non-aqueous solvents and suspension solvents. Witepsol, macrogol, Tween 61, cacao oil, laurin oil, glycerogelatin, etc. may be used as bases for suppositories.
[0037] The dosage of the pharmaceutical composition of the present invention may vary depending on the formulation method, administration method, administration time and / or administration route of the pharmaceutical composition, etc., and may vary depending on various factors including the type and degree of reaction to be achieved by administering the pharmaceutical composition, the type of individual to be administered, age, body weight, general health condition, symptoms or degree of disease, gender, diet, excretion, and components of other compositions used simultaneously or at different times with the individual, as well as similar factors well known in the pharmaceutical field, and a person with ordinary knowledge in the art can easily determine and prescribe a dosage effective for the intended treatment.
[0038] The dosage of the pharmaceutical composition of the present invention is preferably administered at a concentration of, for example, 0.05 to 5 mg / kg, more preferably 0.1 to 0.4 mg / kg, even more preferably 0.2 to 0.35 mg / kg, and even more preferably 0.25 mg / kg, but the above dosage does not limit the scope of the present invention in any way.
[0039] The administration route and method of administration of the pharmaceutical composition of the present invention may each be independent and are not particularly limited in such manner, and may follow any administration route and method as long as the pharmaceutical composition can reach the intended site.
[0040] The above pharmaceutical composition may be administered orally or by parenteral administration. The parenteral administration methods include, for example, intravenous administration, intraperitoneal administration, intramuscular administration, transdermal administration, or subcutaneous administration.
[0041] The pharmaceutical composition of the present invention may be used alone or in combination with methods using surgery, radiation therapy, hormone therapy, chemotherapy, and biological response modifiers for the prevention or treatment of edema.
[0043] In the case where the composition according to the present invention is a cosmetic composition, the cosmetic composition of the present invention may further include conventional auxiliary agents and carriers, such as antioxidants, stabilizers, solubilizers, vitamins, pigments, fragrances, etc., which are commonly used in cosmetic compositions, in addition to the active ingredients. For example, the cosmetic composition may further include auxiliary ingredients such as glycerin, butylene glycol, polyoxyethylene hydrogenated castor oil, tocopheryl acetate, citric acid, panthenol, squalane, sodium citrate, and allantoin.
[0044] Since the cosmetic composition of the present invention is basically applied to the skin, it can be prepared in any formulation conventionally manufactured by referring to cosmetic compositions in the art. For example, it can be formulated as a solution, suspension, emulsion, paste, gel, cream, lotion, powder, soap, surfactant-containing cleansing, oil, powder foundation, emulsion foundation, wax foundation, and spray, but is not limited thereto. More specifically, it can be prepared in the form of a softening lotion, a nourishing lotion, a nourishing cream, a massage cream, an essence, an eye cream, a cleansing cream, a cleansing foam, a cleansing water, a mask pack, a spray, or a powder.
[0045] In the case where the formulation of the present invention is a paste, cream, or gel, the carrier component may include animal oil, vegetable oil, wax, paraffin, starch, tracanth, cellulose derivative, polyethylene glycol, silicone, bentonite, silica, talc, zinc oxide, etc.
[0046] In the case where the formulation of the present invention is a powder or a spray, the carrier component may include lactose, talc, silica, aluminum hydroxide, calcium silicate, polyamide powder, etc., and in particular, in the case of a spray, it may additionally include a propellant such as chlorofluorohydrocarbon, propane / butane, dimethyl ether, etc.
[0047] In the case where the formulation of the present invention is a solution or an emulsion, the carrier component may include a solvent, a solubilizing agent, an emulsifying agent, etc., and specifically, may include water, ethanol, isopropanol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, propylene glycol, 1,3-butyl glycol oil, glycerol aliphatic ester, polyethylene glycol, fatty acid ester of sorbitan, etc.
[0048] In the case where the formulation of the present invention is a suspension, the carrier component may include a liquid diluent such as water, ethanol, or propylene glycol; a suspending agent such as ethoxylated isostearyl alcohol, polyoxyethylene sorbitol ester, or polyoxyethylene sorbitan ester; and microcrystalline cellulose, aluminum metahydroxide, bentonite, agar, tracanth, etc.
[0049] In the case where the formulation of the present invention is a cleansing agent containing a surfactant, the carrier component may include an aliphatic alcohol sulfate, an aliphatic alcohol ether sulfate, a sulfosuccinic acid monoester, isethionate, an imidazolinium derivative, a methyl taurate, a sarcosinate, a fatty acid amide ether sulfate, an alkylamidobetaine, an aliphatic alcohol, a fatty acid glyceride, a fatty acid diethanolamide, a vegetable oil, a lanolin derivative, an ethoxylated glycerol fatty acid ester, etc.
[0051] The Phellodendron bark extract according to the present invention can be used as a food, health functional food, food additive, or dietary supplement.
[0052] When the above Phellodendron bark extract is used as a food additive, it can be appropriately used according to conventional methods, such as by adding the mixture as is or by mixing it with other foods or food ingredients.
[0053] In addition, the amount of the above Phellodendron bark extract can be appropriately changed according to the purpose of use (prevention, health, or therapeutic treatment), and it is preferable to include it in an amount of 0.01 to 95% by weight relative to the total weight of the food composition, and more preferably in an amount of 1 to 80% by weight. If the content is less than 0.01% by weight, the effect may be negligible, and if it exceeds 95% by weight, it may be uneconomical due to a low rate of increase in effect relative to the amount used.
[0054] As a specific example, when manufacturing food or beverages, the Phellodendron amurense extract of the present invention is added in an amount of 15% by weight or less, preferably 10% by weight or less, relative to the raw material. However, when consumed for a long period for the purpose of health and hygiene or for health control, it may be added in an amount less than the above range, and since there is no problem in terms of safety, the active ingredient may also be used in an amount greater than the above range.
[0055] There are no special restrictions on the types of food mentioned above, but examples of food to which the Phellodendron bark extract of the present invention can be added include meat, sausage, bread, chocolate, candy, snacks, confectionery, pizza, ramen, other noodles, chewing gum, dairy products including ice cream, various soups, beverages, tea, drinks, alcoholic beverages, vitamin complexes, etc., and include all health foods in the conventional sense.
[0056] When the food composition of the present invention is prepared as a beverage, it may include additional ingredients such as various flavoring agents or natural carbohydrates, as in conventional beverages. The natural carbohydrates may include monosaccharides such as glucose and fructose; disaccharides such as maltose and sucrose; natural sweeteners such as dextrin and cyclodextrin; and synthetic sweeteners such as saccharin and aspartame. The natural carbohydrates are included in an amount of 0.01 to 10% by weight, preferably 0.01 to 0.1% by weight, based on the total weight of the food composition of the present invention.
[0057] The food composition of the present invention may include various nutritional agents, vitamins, electrolytes, flavoring agents, coloring agents, pectic acid and its salts, alginic acid and its salts, organic acids, protective colloidal thickeners, pH adjusters, stabilizers, preservatives, glycerin, alcohol, carbonating agents used in carbonated beverages, etc., and may include fruit pulp for the production of natural fruit juices, fruit juice beverages, and vegetable beverages, but is not limited thereto. These ingredients may be used independently or in combination. The proportion of the above additives is not significantly limited, but it is preferable that they be included in the range of 0.01 to 0.1 weight percent with respect to the total weight of the food composition of the present invention.
[0058] In the case of long-term consumption for the purpose of health and hygiene or health control, the food composition of the present invention can be taken for a long period of time because there are no problems in terms of safety.
[0060] When the composition according to the present invention is a quasi-drug composition, the quasi-drug composition of the present invention is a quasi-drug composition intended for lymphedema.
[0061] In the present invention, quasi-drugs refer to articles used for the purpose of diagnosing, treating, improving, alleviating, managing, or preventing diseases of humans or animals, among which the effect is milder than that of pharmaceuticals. For example, according to the Pharmaceutical Affairs Act, quasi-drugs are defined as articles excluding those used for pharmaceutical purposes. These include textile products and rubber products used for the treatment or prevention of diseases in humans and animals, items that have a mild or no direct effect on the human body and are not instruments or machines, and similar items, as well as disinfectants and insecticides for preventing infectious diseases.
[0062] The type or formulation of the quasi-drug composition of the present invention is not particularly limited, but preferably may be a disinfectant cleaner, shower foam, mouthwash, wet wipe, detergent soap, hand wash, humidifier filler, mask, ointment or filter filler, etc.
[0063] When the composition of the present invention is included in a quasi-drug for the purpose of preventing or improving edema, the composition may be used as is, or used together with other quasi-drug ingredients, or appropriately used according to conventional methods. The mixing amount of the active ingredient may be appropriately determined according to the purpose of use, and the quasi-drug composition according to the present invention may contain the Phellodendron amurense extract in an amount of 0.01 to 20 weight% relative to the total weight of the composition.
[0065] Redundant content is omitted out of consideration for the complexity of this specification, and terms not otherwise defined in this specification have the meanings commonly used in the technical field to which this invention belongs.
[0067] The present invention will be described in more detail below through examples. These examples are solely for illustrating the present invention, and it will be obvious to those skilled in the art that the scope of the present invention is not to be interpreted as being limited by these examples.
[0069] [Experimental Example]
[0070] Experimental Example 1. Preparation of Phellodendron amurense extract
[0071] Crushed yellow bark ( Phellodendri Cortex , PC)(Entap Herb) was placed in 70% (v / v) ethanol and boiled for 60 minutes using a reflux device. After filtration, the supernatant was concentrated using a rotary evaporator (Eyela, Tokyo, Japan) and then freeze-dried using a freeze-dryer (Ilshin Lab Co., Ltd., Dongducheon, South Korea) to obtain a final Phellodendron bark extract of 27.65 g (yield 13.8%).
[0073] Experimental Example 2. Experimental animals
[0074] Eight-week-old male ICR mice were purchased from Koatech Inc. (Pyeongtaek, South Korea). The mice were housed in a temperature and humidity-controlled, pathogen-free facility on a 12-hour day-night cycle. An acclimatization period of one week was provided prior to the experiment.
[0076] Experimental Example 3. Lymphedema Animal Model
[0077] Mice were randomly divided into a normal group (Normal), a lymphedema group (Lym), and a lymphedema / Phellodendron bark extract administration group (Lym+PC). Lymphedema induction was performed according to the method of Roh K et al. (2017 herapeutic effects of hyaluronidase on acquired lymphedema using a newly developed mouse limb model. Exp Biol Med 242(6):584-592). The Phellodendron bark extract prepared in Experimental Example 1 was administered orally daily at a dose of 200 mg / kg starting 7 days before surgery. Mice were anesthetized by intraperitoneal administration of Zoletil 50 (Virbac, Carros, France) 0.6 mg / kg and Rompun (Bayer, Leverkusen, Germany) 0.4 mg / kg. Lymphatic vessels were stained by subcutaneous injection of 0.3% methylene blue (Sigma-Aldrich, Burlington, MA, USA) into the right foot. Subsequently, superficial inguinal, popliteal, and iliac lymph nodes were removed using microforceps, and the femoral lymph duct was closed by electrocautery. The incised skin was then sutured.
[0078] When evaluating the effect of Phellodendron amurense administration on edema, 5 to 7 animals were used per group. In addition, protein analysis was performed 3 days after surgery, and 5 animals were used per group.
[0080] Experimental Example 4. Evaluation of Lymphedema Size
[0081] The edema in the lymphedema site was measured using digital calipers (Casio Computer Co., Ltd, Shibuya, Tokyo, Japan). The size of the lymphedema was calculated using the following formula.
[0083] Cross-sectional area (mm²) = π × width × length × 0.25
[0085] Each measurement was repeated three times, and the volume was calculated based on the repeated measurements.
[0087] Experimental Example 5. Tissue Sampling
[0088] After anesthetizing mice with isoflurane (Sigma), tissue samples were collected from the right hind leg, 15 mm away from the surgical site.
[0090] Experimental Example 6. ELISA (Enzyme linked immunosorbent assay)
[0091] IL-6 from the tissue sample collected in Experimental Example 5 above was processed according to the manufacturer's (R&D Systems) manual. Each capture antibody was diluted in PBS (phosphate buffered saline), 0.1 ml was dispensed into a 96-well immunoplate, and the plate was incubated overnight at room temperature. After washing each well with washing buffer (0.5% Tween / PBS), the sample and standard cytokine were diluted in blocking buffer (PBS containing 5% BSA), 0.2 ml was added per well, and the plate was incubated at room temperature for 2 hours. Each well was washed three times with washing buffer and then incubated with a biotin-conjugated secondary antibody for 2 hours. After washing three times with washing buffer, Streptavidin-HRP was diluted in blocking buffer, 0.1 ml was added per well, and the plate was incubated at room temperature for 2 minutes. After washing, 0.1 ml of TMB (BD Pharmingen) solution was added per well, and the reaction was carried out at room temperature for 30 minutes. To stop the reaction, 0.05 ml of 2N H2SO4 solution was added per well, and the absorbance was measured at 450 nm using a 96-well microplate reader. The concentration of the sample was calculated using an equation determined by the standard cytokine concentration and absorbance.
[0093] Experimental Example 7. Western blotting
[0094] The supernatant of the tissue homogenate was diluted with SDS buffer and boiled for 5 minutes. The samples were separated on 8% or 10% SDS-polyacrylamide gels and subsequently transferred to polyvinylidene fluoride (PVDF) membranes. The PVDF membranes were blocked for 1 hour with TBST buffer (Tris-buffered saline with 0.1% Tween20) containing 5% skim milk. Subsequently, the primary antibodies against COX2 (Cayman Chemical, Ann Arbor, MI, USA) and GAPDH (Cell Signaling Technology, Danvers, MA, USA) used were diluted in the 5% skim milk-TBST solution and incubated overnight at 4°C. After the incubation, the PVDF membranes were washed with TBST. The washed PVDF membranes were incubated for 1 hour with the anti-rabbit HRP-conjugated secondary antibody. Immunoreactive bands were detected using EzWestLumi plus (ATTO, Tokyo, Japan) and analyzed using the EZ-Capture MG chemiluminescence imaging system (ATTO, Tokyo, Japan). Band density was quantified using ImageJ software.
[0096] Experimental Example 8. Statistical Analysis
[0097] Statistical analysis was performed using SPSS Windows version 28.0 (IBM Corp., Armonk, NY, USA). Data were expressed as mean ± standard deviation (Mean ± SD). Differences in edema between groups were analyzed using repeated measures ANOVA and Student's t-test. Gene and protein expression data were analyzed using Student's t-test or Fisher's test of least significant difference following ANOVA. A p-value of less than 0.05 was considered statistically significant.
[0099] [Example]
[0100] Example 1. Measurement of lymphedema size in an animal model of lymphedema administered Phellodendron amurense extract
[0101] Tissue samples of the lower extremities from the lymphedema animal model prepared in Experimental Example 3 were collected. The size of the lymphedema in the tissue samples collected from individuals (Lym+PC) administered Phellodendron bark extract was measured using the method of Experimental Example 4. The control group (Lym) in this experiment was the untreated group, consisting of individuals that underwent only lymphedema lower extremity surgery. The results of measuring the size of the lymphedema three days after lower extremity surgery are shown in Figure 1.
[0102] As shown in Figure 1, it was confirmed that the size of the lymphedema in the control group (Lym) increased following lower extremity surgery for lymphedema. In contrast, the size of the lymphedema in the group treated with Phellodendron bark extract (Lym+PC) increased after lower extremity surgery for lymphedema, but it was confirmed that the size was significantly smaller compared to the control group (Lym). The above results indicate that the Phellodendron bark extract of the present invention reduces the size of lymphedema.
[0104] Example 2. Analysis of inflammatory cytokine expression via ELISA in a lymphedema animal model administered Phellodendron bark extract
[0105] Since lymphedema is caused by damage to lymphatic vessels leading to inflammation along with swelling, an experiment was conducted to determine whether the Phellodendron bark extract of the present invention could suppress inflammation in a lymphedema model. Mice undergoing lower limb surgery for lymphedema were sacrificed on the third day, and tissue samples were collected as in Experimental Example 5. The protein expression of the inflammatory cytokine IL-6 in the collected tissue samples was analyzed using the method of Experimental Example 6. The results of confirming the protein expression of IL-6 in the tissue samples are shown in Figure 2.
[0106] As shown in Figure 2, when the expression of IL-6 in tissue samples was confirmed, it was found that the protein expression of IL-6 in the control group (Lym) increased following lower extremity surgery for lymphedema. However, it was found that the protein expression of IL-6 in the group treated with Phellodendron amurense extract (Lym+PC) was significantly reduced compared to the control group (Lym). The above results indicate that the Phellodendron amurense extract of the present invention exhibits an anti-inflammatory effect by regulating the expression of inflammatory cytokines in an animal model of lymphedema.
[0108] Example 3. Analysis of inflammatory COX2 expression via Western blot in a lymphedema animal model administered Phellodendron bark extract
[0109] Since lymphedema is caused by damage to lymphatic vessels leading to inflammation along with swelling, an experiment was conducted to determine whether the Phellodendron bark extract of the present invention could suppress inflammation in a lymphedema model. Mice undergoing lower limb surgery for lymphedema were sacrificed on the third day, and tissue samples were collected as in Experimental Example 5. The protein expression of the inflammatory enzyme COX2 in the collected tissue samples was analyzed using the method of Experimental Example 7. The results of confirming the protein expression of COX2 in the tissue samples are shown in Figure 3.
[0110] As shown in Figure 3, it was confirmed that the protein expression of COX2 increased in the control group (Lym) following lower extremity surgery for lymphedema. However, it was confirmed that the protein expression of COX2 in the group treated with Phellodendron bark extract (Lym+PC) was significantly reduced compared to the control group (Lym). The above results indicate that the Phellodendron bark extract of the present invention exhibits an anti-inflammatory effect by regulating the expression of inflammatory cytokines in an animal model of lymphedema.
[0112] In summary, the inventors prepared a Phellodendron bark extract and confirmed the excellent therapeutic effect of the extract on lymphedema. Specifically, it was confirmed that the Phellodendron bark extract of the present invention significantly reduced swelling of the lower extremities (i.e., the size of lymphedema) in an animal model of lower extremity surgery for lymphedema, and exhibited an anti-inflammatory effect through the regulation of protein expression of inflammatory cytokines. This implies that the Phellodendron bark extract of the present invention exhibits a therapeutic effect on lymphedema without suppressing immunity, unlike existing drugs; thus, the Phellodendron bark extract of the present invention can be utilized in various ways in the field of treating edema and lymphedema.
[0114] Foregoing, specific parts of the present invention have been described in detail. It will be apparent to those skilled in the art that such specific descriptions are merely preferred embodiments and do not limit the scope of the invention. Accordingly, the actual scope of the invention is defined by the appended claims and their equivalents.
Claims
Claim 1 A pharmaceutical composition for the prevention or treatment of edema comprising Phellodendron amurense extract. Claim 2 A pharmaceutical composition for the prevention or treatment of edema, wherein, in claim 1, the edema is lymphedema. Claim 3 A pharmaceutical composition for the prevention or treatment of edema according to claim 1, wherein the Phellodendron bark extract is extracted with one or more solvents selected from water, alcohols having 1 to 4 carbon atoms, and mixed solvents thereof. Claim 4 A pharmaceutical composition for the prevention or treatment of edema according to claim 1, wherein the composition comprises 10 to 1000 mg / kg of Phellodendron amurense extract. Claim 5 A pharmaceutical composition for the prevention or treatment of edema, wherein the Phellodendron amurense extract reduces the size of the edematous area according to claim 1. Claim 6 A pharmaceutical composition for the prevention or treatment of edema, wherein, in claim 1, the Phellodendron amurense extract inhibits inflammation in the edematous area. Claim 7 A pharmaceutical composition for the prevention or treatment of edema, wherein the composition is for administration to a patient who has undergone lymph node resection; or for administration to a patient who has received radiation therapy. Claim 8 A food composition for the prevention or improvement of edema comprising Phellodendron amurense extract. Claim 9 A health functional food composition for the prevention or improvement of edema comprising Phellodendron amurense extract. Claim 10 A cosmetic composition for the prevention or improvement of edema comprising Phellodendron amurense extract. Claim 11 A quasi-drug composition for the prevention or improvement of edema containing Phellodendron amurense extract.
